Sandström T, Asander L, Clemmensen I H, Eklund G, Gnosspelius Y, Klarlund Pedersen B, Persson G, Ravn S, Rosenhall L, Weeke B
Department of Lung Medicine, University Hospital, Umeå, Sweden.
Respiration. 1988;53(1):31-6. doi: 10.1159/000195393.
Sixty-eight asthmatics participated in a dose-finding study on bambuterol, a terbutaline prodrug, administered once every evening. Bambuterol administrations of 0.185, 0.270 and 0.400 mg/kg gave effective and long-lasting bronchodilation, for at least 24 h, with the two higher doses probably close to the maximal effect of the drug. Bambuterol 0.400 mg/kg was associated with more adverse effects than bambuterol 0.185 mg/kg. The side effects were those expected in oral beta 2-agonist treatment and mainly experienced by patients who had not been on oral beta 2-agonists before. The most favourable of the investigated doses was found to be 0.270 mg/kg. It can not be excluded, however, that a somewhat lower dose may still be as beneficial. This will be investigated in forthcoming studies.
68名哮喘患者参与了一项关于班布特罗（特布他林前体药物）的剂量探索研究，该药物每晚服用一次。剂量为0.185、0.270和0.400mg/kg的班布特罗可产生有效且持久的支气管扩张作用，至少持续24小时，其中较高的两个剂量可能接近该药物的最大效应。与0.185mg/kg的班布特罗相比，0.400mg/kg的班布特罗出现的不良反应更多。这些副作用是口服β2受体激动剂治疗中预期会出现的，主要出现在之前未使用过口服β2受体激动剂的患者身上。研究发现最适宜的剂量为0.270mg/kg。然而，不能排除稍低剂量可能同样有益的情况。这将在后续研究中进行探究。
